Effect Of PEGylated Recombinant Human Granulocyte Colony-stimulating Factor On Prevention Of Neutropenia After Chemotherapy For Small Cell Lung Cancer

Objective:1.Compare prophylactic PEGylated recombinant human granulocyte colony stimulating factor(PEG-rhG-CSF),and patients who did not use PEG-rhG-CSF in small cell lung cancer grade 3/4 neutropenia after chemotherapy on morbidity and the number of days of neutropenia disease occurs.2.To observe the change of neutrophil after chemotherapy in patients with PEG-rhG-CSF.Methods:We conducted review and follow-up mainly by telephone,medical consultation,and review of cases,and patient-related follow-up ended on February 1,2018.In this study,GraphPad Prism 5.0 statistical software was used for data analysis.The data obtained were expressed as mean±standard deviation.The comparison of the rates was performed using the x2 test.The comparison between multiple samples was performed using one-way analysis of variance.Measurement data were collected between the two groups.The mean uses an independent sample t-test.A P value of <0.05 was defined as statistically significant.The incidence of neutropenia above grade 3,the duration of neutropenia above grade 3,and the incidence of febrile neutropenia were compared between the treatment group and the control group.Results:1.Case data and clinical features: A total of 35 patients were screened out,including 18 in the treatment group and 17 in the control group.There were 18 patients in the treatment group,including 14 males and 4 females.The age is62.1±8.4 years old.There were 9 cases in an extensive period and 9 cases in a limited period.Seven patients had chemotherapy for EP and eleven patients had EL.The ANC before chemotherapy was 4.86±2.62X109/L,and the WBC before chemotherapy was 7.00±2.57X109/L.There were 17 patients in the control group,including 10 males and 7 females.The age is 64.2±7.5 years old.The limitation period was 6 cases and the extensive period was 11 cases.The chemotherapyregimen was EP in 6 patients and EL in 11 patients.The ANC before chemotherapy was 3.67±1.36 X109/L.The WBC before chemotherapy was 5.67±1.39X109/L.There was no significant difference in WBC and ANC between genders,ages,chemotherapy regimens,and chemotherapy before treatment(P>0.05).2.In the treatment group,after the application of PEG-rhG-CSF,the incidence of grade 3/4 neutropenia was 16.6%,and in the control group,the incidence of grade3/4 neutropenia was 88.2%.There was a significant difference in the incidence of grade 3/4 neutropenia between the two groups(P<0.001).3.The duration of grade 3/4 neutropenia in the treatment group was 1.33 ± 0.57 days.The duration of grade 3/4 neutropenia in the control group was 4.2 ± 2.14 days.There was a difference in the duration of grade 3/4 neutropenia between the two groups(P=0.039).4.On the 21 st day of chemotherapy,the delay rate of chemotherapy in the treatment group was 5.88%,and the chemotherapy group had a delay rate of 11.76%.There was no statistically significant difference in chemotherapy delay rates between the two groups(P=0.33).5.In the treatment group,there were no FN patients;the incidence of FN in the control group was 11.76%.6.The adverse reactions of PEG-rhG-CSF were mild and no serious adverse reactions occurred in the patients.Conclusion:1.Prophylactic use of PEG-rhG-CSF can reduce the incidence of grade 3/4neutropenia after chemotherapy.Reduce the duration of 3/4 neutropenia.2.The prophylactic use of PEG-rhG-CSF can significantly increase the minimum value of ANC after chemotherapy,but there is no significant difference in the time of appearance of the lowest value.